The Filing Desk

Puma Biotechnology

PBYI · Nasdaq · Health Care · Financials, fiscal 2016 to 2025

PBYI · Last close · November 13, 2026
$7.77
Value Puma Biotechnology yourself

Puma Biotechnology's revenue fell 0.9% to $228 million in fiscal 2025. Its operating margin was 16.3%, up from 13.4% a year earlier. Free cash flow was $42 million, up 7.4%. The diluted share count rose 3.2%.

PUMA BIOTECHNOLOGY, INC. Latest fiscal year ended December 31, 2025 10-K filed February 26, 2026 · 0001437749-26-005891 Updated
Revenue
$228M
0.9%
Operating margin
16.3%
2.9 pts
Net income
$31M
2.8%
Free cash flow
$42M
7.4%
Return on capital
48.2%
13.7 pts
Market cap
$413M
Nov 13 close
P/E
16.9x
On $0.46 EPS, 4 qtrs

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Puma Biotechnology does

Puma Biotechnology is a drug company that sells one product, NERLYNX (neratinib), a pill for certain HER2-positive breast cancers. In the United States it is approved for early-stage disease after treatment with trastuzumab-based therapy, and, with another drug, for advanced or metastatic disease after prior treatments.

Puma sells NERLYNX in the United States through its own specialty sales force of approximately 35 sales specialists. Outside the United States it licenses the drug to other companies, which seek approval and sell it in their regions, including Europe, Canada, China and Australia. It earns money from its own sales and from these partners.

It also licensed alisertib from Takeda in September 2022. Alisertib is an experimental drug that blocks a protein called Aurora Kinase A, and Puma plans to test it first in small cell lung cancer and hormone receptor-positive breast cancer. Puma competes with other makers of HER2 breast cancer drugs, such as trastuzumab and tucatinib.

Its biggest risks, as it describes them

  • It depends on a single product, NERLYNX, and has limited sales experience.
  • It may not keep reporting profits.
  • It may be unable to raise more money, and its loan terms limit what it can do.
  • Alisertib is at an early stage and may fail in trials or approval.
  • It relies on a small direct sales force to sell NERLYNX in the United States.
From Puma Biotechnology's annual report on Form 10-K, filed February 26, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow

From fiscal 2023 to 2025, earnings per share grew 16.4% a year and net income 20.0% a year, as new shares raised the share count by 7% and diluted each share's earnings.

Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY21FY22FY23FY24FY25
Cash and short-term investments7046498792
Debt incl. finance leases1021021026823
Net debt (negative means net cash)325653−19−69
Net debt to EBITDA2.5x1.6x1.2x−0.4x−1.4x
Debt to equity—4.7x1.9x0.7x0.2x
Interest coverage0.1x2.0x2.5x2.5x5.6x
Current ratio1.3x1.7x1.6x1.5x2.0x
Quick ratio1.2x1.7x1.5x1.4x1.9x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Puma Biotechnology's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

No officer, director or 10% owner of Puma Biotechnology reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.

From Form 4 filings with the SEC. Grants, option exercises and shares withheld for tax aren't counted. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY23FY24FY25
Piotroski F-score6 of 95 of 98 of 9
Rule of 4014.7%14.7%17.4%
Altman Z''−16.14−16.73−14.13
Accruals ratio−2.4%−3.9%−5.0%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY23FY24FY25
Net income is positivePassPassPass
Cash from operations is positivePassPassPass
Return on assets rosePassPassPass
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assetsPassPassPass
Current ratio roseFailFailPass
Share count didn't riseFailFailFail
Gross margin roseFailFailPass
Revenue rose relative to assetsPassFailPass
F-score6 of 95 of 98 of 9
Companies that report no gross profit are scored on the other eight.

Compare

Put Puma Biotechnology side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
Puma BiotechnologyFY25−0.9%16.3%18.3%48.2%−1.4x8
IDEAYA BiosciencesFY253,024.4%−72.8%−33.6%———Compare
HarrowFY2536.4%11.2%15.8%—5.5x6Compare
Rhythm PharmaceuticalsFY2545.8%−101.2%−61.5%——6Compare
Stoke TherapeuticsFY25404.5%−11.2%24.4%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

10 years of figures

Fiscal yearFY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Income statement
Revenue—28251272225253228236230228
Revenue growth——806.6%8.5%−17.3%12.5%−9.9%3.3%−2.2%−0.9%
Gross profit—22216235186190173173166170
Research and development223208165133987252505562
Operating income−277−292−95−39−30124333137
Net income−276−292−114−76−60−290223031
Diluted EPS (US$)−8.29−7.85−2.99−1.95−1.52−0.720.000.450.620.61
Diluted shares (millions)33373839404145484951
Cash flow
Cash from operations−142−172−2422121−16273942
Capital expenditure4000000000
Free cash flow−146−173−2522121−16273942
Dividends paid0000000000
Share buybacks0000000000
Acquisitions0000000000
Stock-based compensation11710987573733121087
Balance sheet at fiscal year end
Cash and short-term investments22982165112807046498792
Debt incl. finance leases—4815295841021021026823
Total assets253166259235244227222230213216
Total liabilities4311222521725022920017712186
Shareholders' equity210533418−6−2225392130
Margins and ratios
Gross margin—79.9%86.2%86.5%82.5%74.8%75.8%73.4%72.1%74.5%
Operating margin—−1,056.1%−37.7%−14.3%−13.5%0.5%10.4%13.8%13.4%16.3%
Net margin—−1,054.6%−45.2%−27.8%−26.6%−11.5%0.0%9.2%13.1%13.6%
Free cash flow margin—−624.5%−9.8%8.1%0.3%8.2%−6.9%11.4%16.9%18.3%
Rule of 40 (growth + FCF margin)——796.8%16.6%−17.0%20.6%−16.9%14.7%14.7%17.4%
Return on capital——————22.2%33.9%34.4%48.2%
Return on equity−132.8%−221.9%−259.3%−292.1%———57.5%41.6%28.0%
Return on assets−112.1%−139.6%−53.5%−30.6%−25.0%−12.4%0.0%9.5%13.6%14.5%
Net debt to EBITDA—————2.5x1.6x1.2x−0.4x−1.4x
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Puma Biotechnology's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Puma Biotechnology.